- Home
- OCUL vs GLPG Comparison
OCUL vs GLPG Comparison
Compare OCUL & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | GLPG |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 704 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | OCUL | GLPG |
|---|---|---|
| Price | $10.76 | $33.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | $22.90 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 7.6M | 87.0K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,990,000.00 | N/A |
| Revenue This Year | $9.35 | N/A |
| Revenue Next Year | $92.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.48 | N/A |
| 52 Week Low | $6.23 | $22.59 |
| 52 Week High | $16.44 | $37.78 |
Technical Indicators
Market Signals| Indicator | OCUL | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 59.29 | 43.37 |
| Support Level | $10.65 | $31.88 |
| Resistance Level | $12.63 | $33.56 |
| Average True Range (ATR) | 0.75 | 0.74 |
| MACD | 0.40 | -0.10 |
| Stochastic Oscillator | 85.67 | 17.41 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.